Evolution Of Pertussis Epidemics And Effect Of Genotypes On Infection Outcomes And Immunisation
Funder
National Health and Medical Research Council
Funding Amount
$657,781.00
Summary
Pertussis, or whooping cough, is caused by Bordetella pertussis. Despite high vaccine coverage, the incidence of pertussis has increased substantially in recent years in Australia. One of the contributing factors is changes in the pertussis strains. This project will determine the genetic composition and virulence characteristics of epidemic strains in Australia and investigate the effect of these strains on disease severity and vulnerability of vaccinated individuals to infection.
Molecular Typing And Epidemiology Of Bordetella Pertussis In Australia
Funder
National Health and Medical Research Council
Funding Amount
$552,662.00
Summary
Pertussis, commonly known as whooping cough, is an acute respiratory disease caused by Bordetella pertussis. Despite more than half a century of vaccination, pertussis has remained endemic in Australia, causing epidemic outbreaks every 3 to 4 years. Indeed the incidence has been increasing in recent years with over 11,000 cases notified in 2005.Pertussis is the commonest of all vaccine preventable diseases targeted by the Australian standard vaccination schedule. To control pertussis, appropriat ....Pertussis, commonly known as whooping cough, is an acute respiratory disease caused by Bordetella pertussis. Despite more than half a century of vaccination, pertussis has remained endemic in Australia, causing epidemic outbreaks every 3 to 4 years. Indeed the incidence has been increasing in recent years with over 11,000 cases notified in 2005.Pertussis is the commonest of all vaccine preventable diseases targeted by the Australian standard vaccination schedule. To control pertussis, appropriate epidemiological surveillance must be implemented to monitor the circulating B. pertussis strains and emergence of any new strains, in particular those that escape the protection by vaccines. This project will use a novel genomic comparison approach to find variation known as single nucleotide polymorphisms (SNP) present around the genome. We will use these SNPs to analyse a large collection of Australian and worldwide isolates to identify those SNPs most suitable for typing and determine the optimal number of SNPs needed for discrimination. A standardized, consistent and reliable typing method for strain identification will be established. We will further develop an integrated method for detecting known variation in the genes encoding the five acellular vaccine antigens. A combined method for strain identification and detection of antigenic variation will then be developed for culture-independent typing, enabling identification of the strain infecting an individual directly from a clinical sample without the need for culture. This study will establish molecular methods for surveillance of pertussis in Australia, essential for further improvement of acellular pertussis vaccines and public health control measures.Read moreRead less
Reducing Pertussis Burden By Optimising Molecular Epidemiological Surveillance Of Epidemic Bordetella Pertussis In Australia
Funder
National Health and Medical Research Council
Funding Amount
$487,258.00
Summary
Australia has experienced a prolonged epidemic of pertussis from 2008 to 2012 and is currently experiencing another epidemic. In this project, we aim to elucidate the evolutionary dynamics of the epidemics by genome sequencing and develop a practical high throughput culture independent method for epidemiological typing. The outcomes will be highly significant for surveillance of pertussis infections and designing strategies for control and prevention of pertussis.
A Serotype-independent, Broad Spectrum Pneumococcal Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$955,585.00
Summary
Streptococcus pneumoniae (the pneumococcus) is the world’s most formidable bacterial pathogen, causing 1-2 million deaths each year. Existing vaccines provide protection against only a limited proportion of strains and their widespread use is increasing the prevalence of strains against which the vaccines provide no protection. This project aims to translate a novel broadly protective pneumococcal vaccine into the commercial development pipeline.
Improving Subunit Vaccines Against Tuberculosis For Pulmonary Delivery
Funder
National Health and Medical Research Council
Funding Amount
$635,320.00
Summary
Tuberculosis is an enormous health problem globally and remains a threat to Australia because of our proximity to high burden countries. The development of better vaccines against TB is crucial to reducing disease and preventing transmission. We shall develop and test new TB vaccines composed of a protective TB protein and immune-stimulating molecules in dry powder which can be safely delivered to the lungs. This respirable vaccine will be used to protect against TB and boost the effects of BCG.
Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
Impact Of Influenza A Infection On T Cell-mediated Immunity To Pulmonary Tuberculosis.
Funder
National Health and Medical Research Council
Funding Amount
$488,058.00
Summary
Tuberculosis is a leading cause of death worldwide and there is an urgent need to develop better anti-TB vaccines. Infection with respiratory viruses may reduce memory T cell responses to M. tuberculosis (Mtb). This project will investigate if Influenza A infection reduces memory anti-tuberculosis T cell responses in mice previously exposed to Mtb or BCG. We will then use influenza viruses engineered to carry parts of Mtb proteins to boost anti-Mtb T cell responses and the protective effect of B ....Tuberculosis is a leading cause of death worldwide and there is an urgent need to develop better anti-TB vaccines. Infection with respiratory viruses may reduce memory T cell responses to M. tuberculosis (Mtb). This project will investigate if Influenza A infection reduces memory anti-tuberculosis T cell responses in mice previously exposed to Mtb or BCG. We will then use influenza viruses engineered to carry parts of Mtb proteins to boost anti-Mtb T cell responses and the protective effect of BCG.Read moreRead less
Developing A Vaccine To Protect Against Hypervirulent Strains Of Group A Streptococcus
Funder
National Health and Medical Research Council
Funding Amount
$536,850.00
Summary
Epidemic invasive GAS disease is associated with the emergence of the globally disseminated M1T1 clone and is linked to the mutation in the CovR/S regulator. This mutation leads to over- expression of SpyCEP and inhibits recruitment of neutrophils to the site of infection. Inclusion of an immunogenic fragment of SpyCEP into our current vaccine would enhance its efficacy and lead to the development of a vaccine with a wider coverage and better protective efficacy against hypervirulent GAS strains
New Candidate Vaccines To Prevent Tuberculosis: Preclinical Assessment Of Efficacy, Safety And Mechanism Of Protection
Funder
National Health and Medical Research Council
Funding Amount
$594,133.00
Summary
Almost two million people die from tuberculosis (TB) each year. The curent vaccine, BCG, is ineffective at controlling TB and and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with our innovative vaccine technology to develop new vaccines to control TB. We will also try and understand why BCG is not effective, and use this information to further improve TB vaccination.